SecBot SecBot

DNTH

Dianthus Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001690585 Biotech & Drug Discovery
$91.81 −0.67 (−0.72%)
Nov 13 4:00 PM ET · prev $92.48
Market cap
$5.2B
Mid cap
Consensus
Buy
96% Buy or better · 24 analysts
Median target
$134.00
+46% · range $113.00–200.00
1 year
+122.0%
from $41.35 · Nov 17
30 days
+23.2%
from $74.54
52-week range
$36.20–115.96
−21% from high · low Jan 6
Avg volume 20D
923.2K
shares / day
Short interest
9.28M
≈16.5% of shares · +3.2%
Days to cover
10.1
at average volume
Insider net
−$19.0M
0 buyers · 6 sellers · since Aug 10
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
18
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 6 neutral oldest → newest, height = score
Avg score ·High conf. 3/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    6 insiders sold $19.0M.

  • InstitutionsBULLISH

    Q3 2026: 34 added (0 new), 14 trimmed or exited.

  • AnalystsBULLISH

    23 of 24 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +3.2% to 9.28M shares. 10.1 days to cover, ≈16.5% of shares.

  • TrendUPTREND

    4% above its 50-day average.

  • SocialQUIET

    No Reddit mentions this week. Last mention Nov 1.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED1,544,461$136.0M
Assenagon Asset Management S.A.DOUBLED732,246$64.5M
WESTFIELD CAPITAL MANAGEMENT CO LPADD474,253$41.8M
Pictet Asset Management Holding SAADD462,290$40.7M
VANGUARD FIDUCIARY TRUST COADD390,521$34.4M
Fisher Asset Management, LLCDOUBLED272,863$24.0M
Artisan Partners Limited PartnershipTRIM185,825$16.4M
Invesco Ltd.ADD166,302$14.6M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

24 analysts
Buy 96% rate it Buy or better
Strong Buy10Buy13Hold1Sell0Strong Sell0
12-month targets · 16 analysts

Price is below the lowest target. Median implies +46%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Oct 27, 2026Roth Capital
INITIATE
INITIATEBuy
Oct 15, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 11, 2026JP Morgan
INITIATE
INITIATEOverweight
Sep 4, 2026Citigroup
INITIATE
INITIATEBuy
Aug 6, 2026Truist Securities
MAINTAIN
MAINTAINBuy
Aug 6, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$19.0M
sold · 6 insiders
DateInsiderTypeValue
Nov 12, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 12, 2026
EXERCISE$29.2K
Nov 12, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 12, 2026
SELL$1.6M
Nov 12, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 12, 2026
EXERCISE$361.6K
Nov 11, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 11, 2026
EXERCISE$38.0K
Nov 11, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 11, 2026
SELL$274.1K
Nov 11, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 11, 2026
EXERCISE$28.7K
Nov 10, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 10, 2026
SELL$230.8K
Nov 10, 2026
Savitz Ryan
EVP, CFO & CBO
Nov 10, 2026
EXERCISE$28.3K

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$1.03-$1.12–-$0.93+5.2%$460.3K
Current FY-$3.60-$3.77–-$3.46+5.6%$2.5M
Next FY-$4.35-$5.36–-$3.47+5.7%$2.0M
Reddit
Recent posts
All social signals and their track records

Short side

FINRA· Oct 30, 2026
9,276,833
shares short
+3.2%
vs prior settlement
10.1
days to cover
≈16.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 Insider
Savitz Ryan acquired via exercise 1,339 shares
EVP, CFO & CBO @ $21.77 ($29.2K)
Nov 12, 2026 Insider
Savitz Ryan sold 17,724 shares
EVP, CFO & CBO @ $90.56 ($1.6M)
Nov 12, 2026 Insider
Savitz Ryan acquired via exercise 16,385 shares
EVP, CFO & CBO @ $22.07 ($361.6K)
Nov 9, 2026 SEC
Ryan Savitz, an officer of Dianthus Therapeutics, filed a Form 144 notice of intent to sell 124,042 shares of common…
144 · Impact 3/10
Nov 5, 2026 Earnings calendar
DNTH Q3 2026 Earnings Scheduled · 2026-11-05
Nov 4, 2026 SEC
Dianthus Therapeutics reported Q3 2026 financial results with a net loss of $46.6M ($0.81 per share), wider than the…
8-K · Impact 4/10
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · DOUBLED
1,544,461 shares ($136.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 5, 2026
Earnings date
DNTH Q3 2026 Earnings Scheduled · 2026-11-05
Nov 4, 2026
Earnings
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 2026 Financial Results
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential…
Nov 2, 2026
Press release
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company…
Nov 2, 2026
Press release
Dianthus Therapeutics to Participate in Five Investor Conferences During November
NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company…
Oct 30, 2026
Short interest
Short Interest: DNTH up 3% to 9.3M shares
Settlement 2026-10-30 | Days to cover: 10.14 | ≈16.47% of shares outstanding (est.)

SecBot reports

18 filings · 5 press releases · 3 bullish · 3 bearish · 1 mixed · 11 neutral
All DNTH filing & press-release reports (23)